Britain and America have secured a important trade agreement that will keep no import taxes on British medicine exports entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise funding on drugs through the National Health Service (NHS). This move guarantees that import taxes on these crucial exports will remain at zero for a duration of the next three years.
This deal comes after earlier statements to significantly raise tariffs on branded pharmaceutical imports, with figures discussed up to double the cost.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed fairness to American-British medicine commerce," an announcement said.
Trade Importance
Drugs constitute one of the UK's biggest goods shipped to the US, which is easily the primary market for leading British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of the third quarter, the UK sold drugs totaling billions to the US. This figure made up a significant portion of total UK exports in that period.
"This guarantee safeguards jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for medical research," a government official remarked.
Specific NHS Changes
The deal includes several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase overall public funding on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. In the past, rebates were more than 20%.
Recent Tensions
The pact takes place against a long-running tension between the sector and the UK government over medicine costs and approval rates.
This friction were intensified by arguments that American consumers were paying several times more for the same drugs than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been paused or cancelled, while major investments have been pledged toward American operations.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a proportion of its resources over the previous ten-year period.
